Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

The Role of Online Hemodiafiltration in Contemporary Kidney Care

Ronco C, Maduell F, Kalantar-Zadeh K, Madero M, Reis T. The Role of Online Hemodiafiltration in Contemporary Kidney Care. Clin J Am Soc Nephrol. 2025[...]

Lanthanum carbonate lowers serum phosphorus without altering body phosphorus burden in maintenance peritoneal dialysis patients: a randomized crossover trial

Kopple JD, Bross R, Ekramzadeh M, Markovic D, Lyzlov A, Lodebo BT, Mehrotra R, Shah AP. Lanthanum carbonate lowers serum phosphorus without altering body phosphorus[...]

Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes

Everett E, Tiu RA, Zhu B, Feng J, Jackson N, Graham J, Ipp E, Mathioudakis N, Bui AAT, Moin T. Developing and Evaluating a Natural[...]